Publications

  1. Clarke MA, Long BJ, Sherman ME, Lemens MA, Podratz KC, Hopkins MR, Ahlberg LJ, Mc Guire LJ, Laughlin-Tommaso SK, Bakkum-Gamez JN, Wentzensen N. Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. Am J Obstet Gynecol. 2020 Apr 5 Epub 2020 Apr 05
    View PubMed
  2. Sangtani A, Wang C, Weaver A, Hoppman NL, Kerr SE, Abyzov A, Shridhar V, Staub J, Kocher JA, Voss JS, Podratz KC, Wentzensen N, Kisiel JB, Sherman ME, Bakkum-Gamez JN. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. Gynecol Oncol. 2020 Feb; 156 (2):387-392 Epub 2019 Nov 28
    View PubMed
  3. Clarke MA, Long BJ, Sherman ME, Lemens MA, Podratz KC, Hopkins MR, Ahlberg LJ, Mc Guire LJ, Laughlin-Tommaso SK, Wentzensen N, Bakkum-Gamez JN. A prospective clinical cohort study of women at increased risk for endometrial cancer. Gynecol Oncol. 2020 Jan; 156 (1):169-177 Epub 2019 Nov 09
    View PubMed
  4. Kilts TP, Glaser GE, Langstraat CL, Kumar A, Weaver AL, Mc Gree ME, Gostout BS, Podratz KC, Dowdy SC, Cliby WA, Mariani A, Bakkum-Gamez JN. Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer. Gynecol Oncol. 2019 Oct; 155 (1):21-26 Epub 2019 Aug 10
    View PubMed
  5. Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC. Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol. 2018 May; 149 (2):291-296 Epub 2018 Mar 14
    View PubMed
  6. Uccella S, Morris JM, Multinu F, Cliby WA, Podratz KC, Gostout BS, Dowdy SC, Ghezzi F, Makdisi PB, Keeney GL, Link MJ, Mariani A. Primary brain metastases of endometrial cancer: A report of 18 cases and review of the literature. Gynecol Oncol. 2016 Jul; 142: (1)70-75.
    View PubMed
  7. Al Hilli MM, Bakkum-Gamez JN, Mariani A, Cliby WA, Mc Gree ME, Weaver AL, Dowdy SC, Podratz KC. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2016 Feb; 140: (2)270-6.
    View PubMed
  8. AlHilli MM, Bakkum-Gamez JN, Mariani A, Weaver AL, McGree ME, Keeney GL, Jatoi A, Dowdy SC, Podratz KC. Risk-adjusted outcomes in elderly endometrial cancer patients: implications of the contrasting impact of age on progression-free and cause-specific survival. Gynecol Oncol. 2015 Jul; 138(1):133-40. Epub 2015 Apr 17.
    View PubMed
  9. Bakkum-Gamez JN, Wentzensen N, Maurer MJ, Hawthorne KM, Voss JS, Kroneman TN, Famuyide AO, Clayton AC, Halling KC, Kerr SE, Cliby WA, Dowdy SC, Kipp BR, Mariani A, Oberg AL, Podratz KC, Shridhar V, Sherman ME. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol. 2015 Apr; 137 (1):14-22 Epub 2015 Feb 10
    View PubMed
  10. Ren CE, Zhu X, Li J, Lyle C, Dowdy S, Podratz KC, Byck D, Chen HB, Jiang SW. Microarray analysis on gene regulation by estrogen, progesterone and tamoxifen in human endometrial stromal cells. Int J Mol Sci. 2015 Mar 13; 16 (3):5864-85
    View PubMed
  11. Ayeni TA, AlHilli MM, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach? Int J Gynecol Cancer. 2015 Jan; 25 (1):87-91
    View PubMed
  12. Beissel JM, Kendrick ML, Podratz KC, Bakkum-Gamez JN. Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature. Gynecol Oncol Rep. 2014 Dec; 10:25-7 Epub 2014 Sept 28
    View PubMed
  13. Wentzensen N, Bakkum-Gamez JN, Killian JK, Sampson J, Guido R, Glass A, Adams L, Luhn P, Brinton LA, Rush B, d'Ambrosio L, Gunja M, Yang HP, Garcia-Closas M, Lacey JV Jr, Lissowska J, Podratz K, Meltzer P, Shridhar V, Sherman ME. Discovery and validation of methylation markers for endometrial cancer. Int J Cancer. 2014 Oct 15; 135 (8):1860-8 Epub 2014 Mar 31
    View PubMed
  14. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014 Oct; 106 (10) Epub 2014 Sept 30
    View PubMed
  15. AlHilli MM, Mariani A, Bakkum-Gamez JN, Dowdy SC, Weaver AL, Peethambaram PP, Keeney GL, Cliby WA, Podratz KC. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014 Jun; 133 (3):485-93 Epub 2014 Mar 29
    View PubMed
  16. Gonzalez-Bosquet J, Chu YL, Chen HB, Dowdy SC, Podratz KC, Li JP, Jiang SW. Development of an intracellular, dna methyltransferase-specific, and gene-specific assay for studying dynamic dna methylation. Curr Pharm Des. 2014 Apr; 20(11):1664-73.
    View PubMed
  17. Zhou HY, Li JP, Podratz KC, Tipton T, Marzolf S, Chen HB, Jiang SW. Hypomethylation and activation of syncytin-1 gene in endometriotic tissue. Curr Pharm Des. 2014 Apr; 20(11):1786-95.
    View PubMed
  18. Bakkum-Gamez JN, Mariani A, Dowdy SC, Weaver AL, McGree ME, Martin JR, Keeney GL, Jatoi A, Gostout BS, Podratz KC. Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy. Gynecol Oncol. 2014 Mar; 132 (3):578-84 Epub 2014 Jan 14
    View PubMed
  19. Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Weaver AL, McGree ME, Cliby WA, Keeney GL, Thomas G, Mariani A. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol. 2014 Jan; 132 (1):38-43 Epub 2013 Oct 09
    View PubMed
  20. Warner LL, Dowdy SC, Martin JR, Lemens MA, McGree ME, Weaver AL, Podratz KC, Bakkum-Gamez JN. The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Nov; 23 (9):1612-9
    View PubMed
  21. AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Keeney GL, Cliby WA, Mariani A. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol. 2013 Oct; 131(1):103-8. Epub 2013 Jul 09.
    View PubMed
  22. Uccella S, Morris JM, Bakkum-Gamez JN, Keeney GL, Podratz KC, Mariani A. Bone metastases in endometrial cancer: report on 19 patients and review of the medical literature. Gynecol Oncol. 2013 Sep; 130 (3):474-82 Epub 2013 May 15
    View PubMed
  23. Kumar S, Mariani A, Bakkum-Gamez JN, Weaver AL, McGree ME, Keeney GL, Cliby WA, Podratz KC, Dowdy SC. Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol. 2013 Sep; 130(3):441-5. Epub 2013 Jun 05.
    View PubMed
  24. Allensworth SK, Langstraat CL, Martin JR, Lemens MA, McGree ME, Weaver AL, Dowdy SC, Podratz KC, Bakkum-Gamez JN. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol. 2013 Sep; 130 (3):499-504 Epub 2013 June 05
    View PubMed
  25. Bakkum-Gamez JN, Dowdy SC, Borah BJ, Haas LR, Mariani A, Martin JR, Weaver AL, McGree ME, Cliby WA, Podratz KC. Predictors and costs of surgical site infections in patients with endometrial cancer. Gynecol Oncol. 2013 Jul; 130 (1):100-6 Epub 2013 Apr 02
    View PubMed
  26. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013 Jun; 129(3):478-85. Epub 2013 Mar 25.
    View PubMed
  27. AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Kumar S, Keeney GL, Cliby WA, Mariani A. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013 Feb; 128(2):294-9. Epub 2012 Oct 17.
    View PubMed
  28. Bakkum-Gamez JN, Dowdy SC, Borah BJ, Haas LR, Mariani A, Martin JR, Weaver AL, McGree ME, Cliby WA, Podratz KC. Predictors and costs of surgical site infections in patients with endometrial cancer. Obstet Gynecol Surv. 2013; 68(8):567-8.
  29. Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, Drapkin R, Podratz K, Broaddus R, Li J. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013; 14(11):22655-77. Epub 2013 Nov 18.
    View PubMed
  30. Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang SW. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int. J. Mol. Sci.. 2013; 14: (3)6026-43.
    View PubMed
  31. Alhilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Kumar S, Keeney GL, Cliby WA, Mariani A. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Obstet Gynecol Surv. 2013; 68(3):199-200.
  32. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, AlHilli MM, Martin JR, Keeney GL, Dowdy SC, Podratz KC. Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. Gynecol Oncol. 2013 Jan; 128 (1):71-76 Epub 2012 Nov 02
    View PubMed
  33. Dowdy SC, Borah BJ, Bakkum-Gamez JN, Kumar S, Weaver AL, McGree ME, Haas LR, Haas LR, Cliby WA, Podratz KC. Factors predictive of postoperative morbidity and cost in patients with endometrial cancer. Obstet Gynecol. 2012 Dec; 120 (6):1419-27
    View PubMed
  34. Kumar S, Medeiros F, Dowdy SC, Keeney GL, Bakkum-Gamez JN, Podratz KC, Cliby WA, Mariani A. A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer. Gynecol Oncol. 2012 Dec; 127(3):525-31. Epub 2012 Aug 29.
    View PubMed
  35. Dowdy SC, Borah BJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Haas LR, Keeney GL, Mariani A, Podratz KC. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol. 2012 Oct; 127(1):5-10. Epub 2012 Jul 03.
    View PubMed
  36. Bakkum-Gamez JN, Chien J, Clayton AC, Halling KC, Cliby WA, Dowdy SC, Kipp BR, Famuyide A, Mariani A, Oberg AL, Wentzensen N, Sherman M, Podratz KC, Shridhar V. Development of biomarkers in endometrial cancer and its precursor lesions. J Womens Health. 2012 Oct; 21(10):1004.
  37. Bakkum-Gamez JN, Kalogera E, Keeney GL, Mariani A, Podratz KC, Dowdy SC. Conservative Management of Atypical Hyperplasia and Grade I Endometrial Carcinoma in Women of Child-Bearing Age Journal of Gynecologic Surgery. 2012.
  38. Bakkum-Gamez JN, Langstraat CL, Martin JR, Lemens MA, Weaver AL, Allensworth S, Dowdy SC, Cliby WA, Gostout BS, Podratz KC. Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma. Gynecol Oncol. 2012 Jun; 125 (3):614-20 Epub 2012 Feb 24
    View PubMed
  39. AlHilli MM, Dowdy SC, Weaver AL, St Sauver, Keeney GL, Mariani A, Podratz KC, Bakkum-Gamez JN. Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecol Oncol. 2012 Apr; 125(1):109-13. Epub 2011 Dec 28.
    View PubMed
  40. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N, Dowdy SC. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012 Feb; 124 (2):270-5 Epub 2011 Oct 28
    View PubMed
  41. Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012 Jan; 38(1):340-4. Epub 2011 Dec 05.
    View PubMed
  42. Bakkum-Gamez JN, Kalogera E, Keeney GL, Mariani A, Podratz KC, Dowdy SC. Conservative management of atypical hyperplasia and grade i endometrial carcinoma: Review of the literature and presentation of a series. J Gynecol Surg. 2012; 28(4):262-9.
  43. Bakkum-Gamez JN, Mariani A, Dowdy SC, Weaver AL, McGree ME, Cliby WA, Gostout BS, Stanhope CR, Wilson TO, Podratz KC. The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancer. Gynecol Oncol. 2011 Oct; 123(1):58-64. Epub 2011 Jul 13.
    View PubMed
  44. Uccella S, Cha SS, Melton LJ 3rd, Bergstralh EJ, Boardman LA, Keeney GL, Podratz KC, Ciancio FF, Mariani A. Risk factors for developing multiple malignancies in patients with endometrial cancer. Int J Gynecol Cancer. 2011 Jul; 21 (5):896-901
    View PubMed
  45. Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, Ota T, Mariani A, Podratz KC, Chien J, Shridhar V. Expression and functional significance of HtrA1 loss in endometrial cancer. Clin Cancer Res. 2011 Feb 1; 17(3):427-36. Epub 2010 Nov 23.
    View PubMed
  46. Uccella S, Mariani A, Nagorney DM, Kalra M, Haddock MG, Podratz KC. Resection of the inferior vena cava for an isolated para-aortic recurrence of endometrial cancer: report of a case. Gynecol Oncol. 2010 Oct; 119(1):167-8. Epub 2010 Jul 06.
    View PubMed
  47. Gonzalez Bosquet, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, Keeney GL. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010 Mar; 116(3):419-23. Epub 2009 Nov 05.
    View PubMed
  48. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1; 70 (3):875-82 Epub 2010 Jan 26
    View PubMed
  49. Mariani A, Cha SS, Bergstralh EJ, Boardman LA, Dowdy SC, Keeney GL, Podratz KC, Melton LJ 3rd. Referral and ascertainment bias in patients with synchronous and metachronous endometrial malignancy. Eur J Gynaecol Oncol. 2010; 31 (1):5-9
    View PubMed
  50. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009 Sep; 9(6):555-66.
    View PubMed
  51. Aletti GD, Powless C, Bakkum-Gamez J, Wilson TO, Podratz KC, Cliby WA. Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. Gynecol Oncol. 2009 Jul; 114(1):32-6. Epub 2009 Apr 09.
    View PubMed
  52. Marnitz S, Dowdy S, Lanowska M, Schneider A, Podratz K, Kohler C. Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers. Int J Gynecol Cancer. 2009 Jul; 19(5):974-7.
    View PubMed
  53. Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet. 2009 May; 105: (2)110-1.
    View PubMed
  54. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, Podratz KC, Cliby WA. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009 Apr; 208 (4):614-20
    View PubMed
  55. Thomas MB, Keeney GL, Podratz KC, Dowdy SC. Endometrial stromal sarcoma: treatment and patterns of recurrence. Int J Gynecol Cancer. 2009 Feb; 19 (2):253-6
    View PubMed
  56. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009 Jan 13; 100 (1):89-95 Epub 2008 Dec 16
    View PubMed
  57. Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol Oncol. 2009 Jan; 112(1):16-21. Epub 2008 Nov 22.
    View PubMed
  58. Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009 Jan; 112(1):22-7. Epub 2008 Oct 23.
    View PubMed
  59. Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A. Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol. 2008 Dec; 111 (3):418-24 Epub 2008 Oct 02
    View PubMed
  60. Brown Jones M, Neuper C, Clayton A, Mariani A, Konecny G, Thomas MB, Keeney G, Hartmann L, Podratz KC. Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer. 2008 Oct 1; 123: (7)1699-703.
    View PubMed
  61. Jiang SW, Li J, Podratz K, Dowdy S. Application of DNA methylation biomarkers for endometrial cancer management. Expert Rev Mol Diagn. 2008 Sep; 8(5):607-16.
    View PubMed
  62. Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, Dowdy SC. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. 2008 Jun; 109 (3):335-9 Epub 2008 Apr 03
    View PubMed
  63. Konecny GE, Agarwal R, Keeney GA, Winterhoff B, Jones MB, Mariani A, Riehle D, Neuper C, Dowdy SC, Wang HJ, Morin PJ, Podratz KC. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008 May; 109 (2):263-9 Epub 2008 Mar 07
    View PubMed
  64. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, Podratz KC. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008 Apr; 109 (1):11-8 Epub 2008 Mar 04
    View PubMed
  65. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008 Mar 25; 98 (6):1076-84 Epub 2008 Mar 11
    View PubMed
  66. Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, Podratz KC, Dowdy SC. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008 Feb; 108(2):293-7. Epub 2007 Dec 21.
    View PubMed
  67. Mariani A, Camilleri M, Petersen IA, Ward EM, Farrugia G, Kelly DG, Podratz KC. Audit of suspected chronic intestinal pseudo-obstruction in patients with gynecologic cancer. Eur J Gynaecol Oncol. 2008; 29(6):578-82.
    View PubMed
  68. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007 Dec; 197(6):676.e1-7.
    View PubMed
  69. Dowdy SC, Mariani A, Bakkum JN, Cliby WA, Keeney GL, Podratz KC. Treatment of pulmonary recurrences in patients with endometrial cancer. Gynecol Oncol. 2007 Nov; 107(2):242-7. Epub 2007 Sep 17.
    View PubMed
  70. Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007 Nov; 107(2):190-3. Epub 2007 Sep 06.
    View PubMed
  71. Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007 Nov; 107(2):186-9. Epub 2007 Aug 3.
    View PubMed
  72. Zhou XC, Dowdy SC, Podratz KC, Jiang SW. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol. 2007 Oct; 107(1):143-53. Epub 2007 Aug 13.
    View PubMed
  73. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS, Cliby WA. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007 Oct; 107 (1):99-106 Epub 2007 June 28
    View PubMed
  74. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, Gold MA, Mcmeekin DS, Modesitt S, Cooper AL, Powell MA, Mutch DG, Nag S, Alvarez RD, Cohn DE. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007 Jul-Aug; 17(4):886-9. Epub 2007 Feb 16.
    View PubMed
  75. Gonzalez Bosquet J, Magrina JF, Magtibay PM, Gaffey TA, Cha SS, Jones MB, Podratz KC, Cliby WA. Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. Gynecol Oncol. 2007 Jun; 105(3):742-6.
    View PubMed
  76. Cohn DE, Woeste EM, Cacchio S, Zanagnolo VL, Havrilesky LJ, Mariani A, Podratz KC, Huh WK, Whitworth JM, McMeekin DS, Powell MA, Boyd E, Phillips GS, Fowler JM. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol. 2007 May; 109(5):1062-7.
    View PubMed
  77. Jiang S, Dowdy SC, Meng XW, Wang ZY, Jones MB, Podratz KC, Jiang SW. Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells. Gynecol Oncol. 2007 May; 105(2):493-500.
    View PubMed
  78. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007 Apr; 105(1):84-9. Epub 2006 Dec 08.
    View PubMed
  79. Bardia A, Thompson CA, Podratz KC, Okuno SH. Bizarre big belly ball: intraabdominal abscess mimicking stauffer syndrome secondary to uterine leiomyosarcoma. Eur J Gynaecol Oncol. 2007; 28: (2)134-6.
    View PubMed
  80. Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol. 2007 Jan; 104(1):212-6. Epub 2006 Oct 04.
    View PubMed
  81. Aletti GD, Dowdy S, Podratz KC, Cliby WA. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol. 2006 Dec; 195(6):1862-8.
    View PubMed
  82. Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol. 2006 Dec; 103(3):797-801. Epub 2006 Oct 18.
    View PubMed
  83. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther. 2006 Nov; 5(11):2767-76.
    View PubMed
  84. Xiong Y, Dowdy SC, Eberhardt NL, Podratz KC, Jiang SW. hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecol Oncol. 2006 Oct; 103 (1):321-8 Epub 2006 May 15
    View PubMed
  85. Podratz KC. Quality improvement in gynecologic surgery: the new frontier. Am J Obstet Gynecol. 2006 Oct; 195(4):891-5.
    View PubMed
  86. Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006 Oct; 203(4):521-6. Epub 2006 Aug 23.
    View PubMed
  87. Magtibay PM, Adams PB, Silverman MB, Cha SS, Podratz KC. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2006 Aug; 102(2):369-74. Epub 2006 Apr 24.
    View PubMed
  88. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon (vol 100, pg 33, 2006). Gynecol Oncol. 2006 Jun; 101(3):553.
  89. Jones MB, Houwink AP, Freeman BK, Greenwood TM, Lafky JM, Lingle WL, Berchuck A, Maxwell GL, Podratz KC, Maihle NJ. The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. J Soc Gynecol Investig. 2006 May; 13(4):304-11.
    View PubMed
  90. Mariani A, Dowdy SC, Cliby WA, Haddock MG, Keeney GL, Lesnick TG, Podratz KC. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol. 2006 May; 101(2):200-8. Epub 2006 Feb 28.
    View PubMed
  91. Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, Podratz KC. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol. 2006 May; 101(2):280-6.
    View PubMed
  92. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006 Apr; 17(4):597-604. Epub 2006 Jan 10.
    View PubMed
  93. Mariani A, Sebo TJ, Cliby WA, Keeney GL, Riehle DL, Lesnick TG, Podratz KC. Role of bcl-2 in endometrioid corpus cancer: an experimental study. Anticancer Res. 2006 Mar-Apr; 26(2A):823-7.
    View PubMed
  94. Long HJ 3rd, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM Jr, Kardinal CG, Wos EJ. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecol Oncol. 2006 Mar; 100(3):501-5. Epub 2005 Sep 26.
    View PubMed
  95. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006 Feb; 100(2):283-7. Epub 2005 Sep 22.
    View PubMed
  96. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006 Feb 1; 66(3):1630-9.
    View PubMed
  97. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006 Jan; 107(1):77-85.
    View PubMed
  98. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006 Jan; 100(1):33-7. Epub 2005 Sep 08.
    View PubMed
  99. Magtibay PM, Salmon Z, Keeney GL, Podratz KC. Aggressive angiomyxoma of the female pelvis and perineum: a case series. Int J Gynecol Cancer. 2006 Jan-Feb; 16 (1):396-401
    View PubMed
  100. Bosquet JG, Merideth MA, Podratz KC, Nagorney DM. Hepatic resection for metachronous metastases from ovarian carcinoma. HPB (Oxford). 2006; 8 (2):93-6
    View PubMed
  101. Magtibay PM, Nyholm JL, Hernandez JL, Podratz KC. Ovarian remnant syndrome. American Journal of Obstetrics & Gynecology. 2005 Dec; 193(6):2062-6.
    View PubMed
  102. Dowdy SC, Gostout BS, Shridhar V, Wu X, Smith DI, Podratz KC, Jiang SW. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol. 2005 Oct; 99(1):126-34.
    View PubMed
  103. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC, Jiang SW. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol. 2005 Oct; 99 (1):135-41
    View PubMed
  104. Mariani A, Sebo TJ, Katzmann JA, Riehle DL, Dowdy SC, Keeney GL, Lesnick TG, Podratz KC. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res. 2005 Jul-Aug; 25(4):2921-7.
    View PubMed
  105. Mariani A, Dowdy SC, Keeney GL, Haddock MG, Lesnick TG, Podratz KC. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005 Jun; 97(3):820-7.
    View PubMed
  106. Gonzalez Bosquet J, Magrina JF, Gaffey TA, Hernandez JL, Webb MJ, Cliby WA, Podratz KC. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol. 2005 Jun; 97(3):828-33.
    View PubMed
  107. Xiong Y, Dowdy SC, Podratz KC, Jin F, Attewell JR, Eberhardt NL, Jiang SW. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 2005 Apr 1; 65 (7):2684-9
    View PubMed
  108. Mariani A, Sebo TJ, Katzmann JA, Roche PC, Keeney GL, Lesnick TG, Podratz KC. Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol. 2005 Mar; 96(3):594-600.
    View PubMed
  109. Xiong Y, Dowdy SC, Xue A, Shujuan J, Eberhardt NL, Podratz KC, Jiang SW. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecol Oncol. 2005 Mar; 96 (3):601-9
    View PubMed
  110. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R. Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol. 2005 Feb; 96: (2)368-73.
    View PubMed
  111. Dowdy SC, Metzinger DS, Gebhart JB, Srivatsa P, Haddock MG, Suman VJ, Podratz KC. Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol Oncol. 2005 Feb; 96(2):389-94.
    View PubMed
  112. Jin F, Dowdy SC, Xiong Y, Eberhardt NL, Podratz KC, Jiang SW. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecol Oncol. 2005 Feb; 96 (2):531-8
    View PubMed
  113. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu DC, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):306-18.
    View PubMed
  114. Mariani A, Dowdy S, Podratz KC. Predictors of poor prognosis in endometrial cancer: 0006 International Journal of Gynecological Cancer. 2005; 15 (2):401-2
  115. Mariani A, Dowdy SC, Keeney GL, Long HJ, Lesnick TG, Podratz KC. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol. 2004 Oct; 95(1):120-6.
    View PubMed
  116. Cliby W, Dowdy S, Feitoza SS, Gostout BS, Podratz KC. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol. 2004 Sep; 94(3):655-60.
    View PubMed
  117. Jatoi A, Podratz KC, Gill P, Hartmann LC. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. J Support Oncol. 2004 Jul-Aug; 2(4):323-34; discussion 334-7.
    View PubMed
  118. Mariani A, Keeney GL, Aletti G, Webb MJ, Haddock MG, Podratz KC. Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol. 2004 Mar; 92(3):833-8.
    View PubMed
  119. Croak AJ, Gebhart JB, Klingele CJ, Schroeder G, Lee RA, Podratz KC. Characteristics of patients with vaginal rupture and evisceration. Obstet Gynecol. 2004 Mar; 103(3):572-6.
    View PubMed
  120. Dowdy SC, Constantinou CL, Hartmann LC, Keeney GL, Suman VJ, Hillman DW, Podratz KC. Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. Gynecol Oncol. 2003 Dec; 91 (3):563-8
    View PubMed
  121. Gonzalez Bosquet J, Kinney WK, Russell AH, Gaffey TA, Magrina JF, Podratz KC. Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2003 Oct 1; 57 (2):419-24
    View PubMed
  122. Martinez AA, Weiner S, Podratz K, Armin AR, Stromberg JS, Stanhope R, Sherman A, Schray M, Brabbins DA. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol Oncol. 2003 Sep; 90(3):537-46.
    View PubMed
  123. Carley ME, Rickard DJ, Gebhart JB, Webb MJ, Podratz KC, Spelsberg TC. Distribution of estrogen receptors alpha and beta mRNA in mouse urogenital tissues and their expression after oophorectomy and estrogen replacement. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Jun; 14 (2):141-5 Epub 2003 Feb 27
    View PubMed
  124. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol. 2003 May; 89 (2):236-42
    View PubMed
  125. Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003 Apr; 89 (1):16-21
    View PubMed
  126. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12 (2):103-13
    View PubMed
  127. Mariani A, Sebo TJ, Webb MJ, Riehle D, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev. 2003; 27 (6):434-41
    View PubMed
  128. Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002 Dec; 87 (3):274-80
    View PubMed
  129. Long HJ 3rd, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, Levitt R, Nair S, Hatfield AK, Knost JA. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol. 2002 Dec; 25 (6):547-51
    View PubMed
  130. Mariani A, Webb MJ, Keeney GL, Haddock MG, Aletti G, Podratz KC. Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol. 2002 Oct; 87 (1):112-7
    View PubMed
  131. Stewart KD, Martinez AA, Weiner S, Podratz K, Stromberg JS, Schray M, Mitchell C, Sherman A, Chen P, Brabbins DA. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54(2):527-35.
    View PubMed
  132. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol. 2002 Jul; 86 (1):38-44
    View PubMed
  133. Gostout BS, Cliby WA, Podratz KC. Prevention and management of acute intraoperative bleeding. Clin Obstet Gynecol. 2002 Jun; 45 (2):481-91
    View PubMed
  134. Dowdy SC, Boardman CH, Wilson TO, Podratz KC, Hartmann LC, Long HJ. Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. Am J Obstet Gynecol. 2002 Jun; 186 (6):1167-73
    View PubMed
  135. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002 Mar; 84(3):437-42.
    View PubMed
  136. Maihle NJ, Lafky JM, Baron AT, Boardman CH, Greenwood TM, Christensen TA, Reiter JL, Cora EM, Lee H, Suman VJ, Fishman DA, Perez EA, Podratz KC. EGF receptor/ErbB isoforms as serum biomarkers in breast and ovarian cancer. Journal of Clinical Ligand Assay. 2002 Spr; 25(1):57-60.
  137. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002; 107:247-58
    View PubMed
  138. Gebhart JB, Rickard DJ, Barrett TJ, Lesnick TG, Webb MJ, Podratz KC, Spelsberg TC. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol. 2001 Dec; 185(6):1325-30; discussion 1330-1.
    View PubMed
  139. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev. 2001 Nov; 10 (11):1175-85
    View PubMed
  140. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol. 2001 Oct; 83(1):72-80.
    View PubMed
  141. Dowdy SC, O'Kane DJ, Keeney GL, Boyd J, Podratz KC. Telomerase activity in sex cord-stromal tumors of the ovary. Gynecol Oncol. 2001 Aug; 82(2):257-60.
    View PubMed
  142. Mariani A, Webb MJ, Keeney GL, Podratz KC. Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer. Gynecol Oncol. 2001 Apr; 81(1):100-4.
    View PubMed
  143. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Hematogenous dissemination in corpus cancer. Gynecol Oncol. 2001 Feb; 80(2):233-8.
    View PubMed
  144. Mariani A, Webb MJ, Rao SK, Lesnick TG, Podratz KC. Significance of pathologic patterns of pelvic lymph node metastases in endometrial cancer. Gynecol Oncol. 2001 Feb; 80(2):113-20.
    View PubMed
  145. Mariani A, Nascimento AG, Webb MJ, Sim FH, Podratz KC. Surgical management of desmoid tumors of the female pelvis. J Am Coll Surg. 2000 Aug; 191 (2):175-83
    View PubMed
  146. Mariani A, Sebo TJ, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol. 2000 Jun; 182(6):1535-44.
    View PubMed
  147. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000 Jun; 182(6):1506-19.
    View PubMed
  148. Gebhart JB, Roche PC, Keeney GL, Lesnick TG, Podratz KC. Assessment of inhibin and p53 in granulosa cell tumors of the ovary. Gynecol Oncol. 2000 May; 77(2):232-6.
    View PubMed
  149. Silverman MB, Roche PC, Kho RM, Keeney GL, Li H, Podratz KC. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol. 2000 Apr; 77(1):1-7.
    View PubMed
  150. Mariani A, Webb MJ, Galli L, Podratz KC. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol. 2000 Mar; 76(3):348-56.
    View PubMed
  151. Magrina JF, Gonzalez-Bosquet J, Weaver AL, Gaffey TA, Leslie KO, Webb MJ, Podratz KC. Squamous cell carcinoma of the vulva stage IA: long-term results. Gynecol Oncol. 2000 Jan; 76(1):24-7.
    View PubMed
  152. Ramsey PS, Podratz KC. Acute pancreatitis after gynecologic and obstetric surgery. Am J Obstet Gynecol. 1999 Sep; 181 (3):542-6
    View PubMed
  153. Villeneuve JB, Silverman MB, Alderete B, Cliby WA, Li H, Croghan GA, Podratz KC, Jenkins RB. Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. Genes Chromosomes Cancer. 1999 May; 25 (1):65-9
    View PubMed
  154. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1999 Feb; 8 (2):129-37
    View PubMed
  155. Magrina JF, Goodrich MA, Lidner TK, Weaver AL, Cornella JL, Podratz KC. Modified radical hysterectomy in the treatment of early squamous cervical cancer. Gynecol Oncol. 1999 Feb; 72(2):183-6.
    View PubMed
  156. Frias AE Jr, Li H, Keeney GL, Podratz KC, Woodruff TK. Preoperative serum level of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma. Cancer. 1999 Jan 15; 85 (2):465-71
    View PubMed
  157. Magrina JF, Gonzalez-Bosquet J, Weaver AL, Gaffey TA, Webb MJ, Podratz KC, Cornella JL. Primary squamous cell cancer of the vulva: radical versus modified radical vulvar surgery. Gynecol Oncol. 1998 Oct; 71(1):116-21.
    View PubMed
  158. Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods. 1998 Oct 1; 219 (1-2):23-43
    View PubMed
  159. Gostout BS, Podratz KC, McGovern RM, Persing DH. Cervical cancer in older women: a molecular analysis of human papillomavirus types, HLA types, and p53 mutations. Am J Obstet Gynecol. 1998 Jul; 179 (1):56-61
    View PubMed
  160. Boardman LA, Thibodeau SN, Schaid DJ, Lindor NM, McDonnell SK, Burgart LJ, Ahlquist DA, Podratz KC, Pittelkow M, Pittelkow M, Hartmann LC. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998 Jun 1; 128 (11):896-9
    View PubMed
  161. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. Classic Papers and Comments J Clin Oncol. 1998; 3(1):58-63.
  162. Barrette BA, Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Podratz KC, Roche PC. Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma. Mayo Clin Proc. 1997 Oct; 72(10):925-9.
    View PubMed
  163. Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Harmsen WS, Ziesmer SC, Roche PC, Podratz KC. Expression of nm23/nucleoside diphosphate kinase-A protein in endometrial carcinoma. Gynecol Oncol. 1997 Aug; 66(2):238-45.
    View PubMed
  164. Garton GR, Gunderson LL, Webb MJ, Wilson TO, Cha SS, Podratz KC. Intraoperative radiation therapy in gynecologic cancer: update of the experience at a single institution. Int J Radiat Oncol Biol Phys. 1997 Mar 1; 37 (4):839-43
    View PubMed
  165. Haddock MG, Petersen IA, Webb MJ, Wilson TO, Podratz KC, Gunderson LL. IORT for locally advanced gynecological malignancies. Front Radiat Ther Oncol. 1997; 31:256-9
    View PubMed
  166. Barrette B, Srivatsa P, Cliby W, Keeney G, Suman V, Podratz K, Roche P. Over-expression of p34(cdc2) protein kinase in epithelial ovarian carcinoma. Mayo Clin Proc. 1997; 72(10):925-929.
  167. Lim PC, Tester D, Cliby W, Ziesmer SC, Roche PC, Hartmann L, Thibodeau SN, Podratz KC, Jenkins RB. Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability. Clin Cancer Res. 1996 Nov; 2: (11)1907-11.
    View PubMed
  168. Zanetta G, Keeney GL, Cha SS, Farr GH Jr, Katzmann JA, Wieand HS, Edmonson JH, Podratz KC. Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: its importance in long-term survival. Am J Obstet Gynecol. 1996 Nov; 175 (5):1217-25
    View PubMed
  169. Evans MP, Podratz KC. Endometrial neoplasia: prognostic significance of ploidy status. Clin Obstet Gynecol. 1996 Sep; 39 (3):696-706
    View PubMed
  170. Gurian KV, Podratz KC, Elg SA, Twiggs LB, Lurain JR, Wagner JM, Gleich GJ. Major basic protein as a marker of malignant potential in trophoblastic neoplasia. Am J Obstet Gynecol. 1996 Sep; 175 (3 Pt 1):632-7
    View PubMed
  171. Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ, Hu TC, Podratz KC. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol. 1996 Aug; 62(2):192-8.
    View PubMed
  172. Zanetta G, Keeney GL, Cha SS, Wieand HS, Katzmann JA, Podratz KC. DNA index by flow cytometric analysis: an additional prognostic factor in advanced ovarian carcinoma without residual disease after primary operation. Gynecol Oncol. 1996 Aug; 62(2):208-12.
    View PubMed
  173. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, Teneriello M, Averette HA, Sevin BU. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996 Apr; 61(1):3-10.
    View PubMed
  174. Srivatsa PJ, Cliby WA, Keeney GL, Dodson MK, Suman VJ, Roche PC, Podratz KC. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma. Gynecol Oncol. 1996 Mar; 60(3):363-72.
    View PubMed
  175. Zanetta GM, Keeney GL, Kimlinger TK, Katzmann JA, Podratz KC. Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma. Gynecol Oncol. 1996 Feb; 60(2):213-6.
    View PubMed
  176. Dodson MK, Cliby WA, Pettavel PP, Keeney GL, Podratz KC. Female urethral adenocarcinoma: evidence for more than one tissue of origin? Gynecol Oncol. 1995 Dec; 59(3):352-7.
    View PubMed
  177. Magrina JF, Goodrich MA, Weaver AL, Podratz KC. Modified radical hysterectomy: morbidity and mortality. Gynecol Oncol. 1995 Nov; 59(2):277-82.
    View PubMed
  178. Podratz KC, Ferguson LK, Hoverman VR, Lee RA, Symmonds RE. Abdominal sacral colpopexy for posthysterectomy vaginal vault descensus. Obstet Gynecol Surv. 1995 Oct; 50(10):719-720.
  179. Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC. c-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer. 1995 Jun 15; 75 (12):2891-6
    View PubMed
  180. Cliby WA, Dodson MK, Podratz KC. Uterine prolapse complicated by endometrial cancer. Am J Obstet Gynecol. 1995 Jun; 172 (6):1675-80; discussion 1680-3
    View PubMed
  181. Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz KC. Surgical treatment of patients with stages ib and iia carcinoma of the cervix and palpably positive pelvic lymph. Gynecol Oncol. 1995 May; 57:145-149.
    View PubMed
  182. Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz KC. Identification of a low-risk subset of patients with stage IB invasive squamous cancer of the cervix possibly suited to less radical surgical treatment. Gynecol Oncol. 1995 Apr; 57(1):3-6.
    View PubMed
  183. Podratz KC, Ferguson LK, Hoverman VR, Lee RA, Symmonds RE. Abdominal sacral colpopexy for posthysterectomy vaginal vault descensus. Journal of Pelvic Surgery. 1995; 1:18-23.
  184. Podratz KC, Cliby WA. Second-look surgery in the management of epithelial ovarian carcinoma. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S128-33.
    View PubMed
  185. Dodson MK, Cliby WA, Keeney GL, Peterson MF, Podratz KC. Skene's gland adenocarcinoma with increased serum level of prostate-specific antigen. Gynecol Oncol. 1994 Nov; 55 (2):304-7
    View PubMed
  186. Cliby WA, Dodson MK, Podratz KC. Cervical cancer complicated by pregnancy: episiotomy site recurrences following vaginal delivery. Obstet Gynecol. 1994 Aug; 84(2):179-82.
    View PubMed
  187. van Winter JT, Simmons PS, Podratz KC. Surgically treated adnexal masses in infancy, childhood, and adolescence. Am J Obstet Gynecol. 1994 Jun; 170 (6):1780-6; discussion 1786-9
    View PubMed
  188. Srivatsa PJ, Keeney GL, Podratz KC. Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome. Gynecol Oncol. 1994 May; 53(2):256-64.
    View PubMed
  189. Dodson MK, Cliby WA, Xu HJ, DeLacey KA, Hu SX, Keeney GL, Li J, Podratz KC, Jenkins RB, Benedict WF. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res. 1994 Feb 1; 54(3):610-3.
    View PubMed
  190. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994 Jan; 12: (1)64-9.
    View PubMed
  191. Jenkins RB, Bartelt D Jr, Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, Podratz K, Keeney G, Hartmann L, Hartmann L. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet. 1993 Nov; 71 (1):76-86
    View PubMed
  192. Dodson MK, Hartmann LC, Cliby WA, DeLacey KA, Keeney GL, Ritland SR, Su JQ, Podratz KC, Jenkins RB. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res. 1993 Oct 1; 53(19):4456-60.
    View PubMed
  193. Cliby W, Sarkar G, Ritland SR, Hartmann LC, Podratz KC, Jenkins RB. Absence of prohibition gene mutations in human epithelial ovarian tumors. Gynecol Oncol. 1993 Jul; 50:34-37.
    View PubMed
  194. Helm CW, Kinney WK, Keeney G, Lawrence WD, Frank TS, Gore H, Reynolds RK, Soong SJ, Partridge EE, Roberts J, Podratz K, Shingleton HM, Podratz KC. A matched study of surgically treated stage IB adenosquamous carcinoma and adenocarcinoma of the uterine cervix. Int J Gynecol Cancer. 1993 Jul; 3 (4):245-249
    View PubMed
  195. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC, Jenkins RB. Human epithelial ovarian cancer allelotype. Cancer Res. 1993 May 15; 53(10 Suppl):2393-8.
    View PubMed
  196. Leiserowitz GS, Harris SA, Subramaniam M, Keeney GL, Podratz KC, Spelsberg TC. The proto-oncogene c-fms is overexpressed in endometrial cancer. Gynecol Oncol. 1993 May; 49(2):190-6.
    View PubMed
  197. Podratz KC, Wilson TO, Gaffey TA, Cha SS, Katzmann JA. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol. 1993 Apr; 168 (4):1206-13; discussion 1213-5
    View PubMed
  198. Garton GR, Gunderson LL, Webb MJ, Wilson TO, Martenson JA Jr, Cha SS, Podratz KC. Intraoperative radiation therapy in gynecologic cancer: the Mayo Clinic experience. Gynecol Oncol. 1993 Mar; 48: (3)328-32.
    View PubMed
  199. Podratz KC, Kinney WK. Second-look operation in ovarian cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1551-8.
    View PubMed
  200. Van Winter JT, Podratz KC, Gaffey TA. Sclerosing stromal tumor of the ovary in a 13-year-old girl. Adolesc Pediatr Gynecol. 1993; 6:164-165.
  201. Williams TJ, Podratz KC. Familial ovarian cancer and prophylactic oophorectomy. Postgrad Obstet Gynecol. 1993; 13:1-5.
  202. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992 Nov; 47 (2):179-85
    View PubMed
  203. Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha SS, Wieand HS, Keeney GL, Roche PC. Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival. Gynecol Oncol. 1992 Nov; 47 (2):191-5
    View PubMed
  204. Woods JE, Alter G, Meland B, Podratz K. Experience with vaginal reconstruction utilizing the modified Singapore flap. Plast Reconstr Surg. 1992 Aug; 90(2):270-4.
    View PubMed
  205. Zanetta GM, Katzmann JA, Keeney GL, Kinney WK, Cha SS, Podratz KC. Flow-cytometric DNA analysis of stages IB and IIA cervical carcinoma. Gynecol Oncol. 1992 Jul; 46 (1):13-9
    View PubMed
  206. Podratz KC. New techniques in gynecologic oncology. Clin Obstet Gynecol. 1992 Mar; 35:1-2.
    View PubMed
  207. Kinney WK, Egorshin EV, Ballard DJ, Podratz KC. Long-term survival and sequelae after surgical management of invasive cervical carcinoma diagnosed at the time of simple hysterectomy. Gynecol Oncol. 1992 Jan; 44 (1):24-7
    View PubMed
  208. Lentz SS, Cha SS, Wieand HS, Podratz KC. Stage I ovarian epithelial carcinoma: survival analysis following definitive treatment. Gynecol Oncol. 1991 Dec; 43 (3):198-202
    View PubMed
  209. Gibbons S, Martinez A, Schray M, Podratz K, Stanhope R, Garton G, Weiner S, Brabbins D, Malkasian G. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1991 Sep; 21(4):1019-25.
    View PubMed
  210. Stanhope CR, Webb MJ, Podratz KC. Pelvic exenteration for recurrent cervical cancer. Clin Obstet Gynecol. 1990 Dec; 33 (4):897-909
    View PubMed
  211. Lentz SS, Kovach JS, McKean DJ, Wieand HS, Podratz KC. Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma. Gynecol Oncol. 1990 Aug; 38 (2):191-6
    View PubMed
  212. Shaw EG, Gunderson LL, Martin JK, Beart RW, Martin JK, Nagorney DM, Podratz KC. Peripheral nerve and ureteral tolerance to intraoperative radiation therapy: clinical and dose-response analysis. Radiother Oncol. 1990 Jul; 18 (3):247-55
    View PubMed
  213. Britton LC, Wilson TO, Gaffey TA, Cha SS, Wieand HS, Podratz KC. DNA ploidy in endometrial carcinoma: major objective prognostic factor. Mayo Clin Proc. 1990 May; 65 (5):643-50
    View PubMed
  214. Wilson TO, Podratz KC, Gaffey TA, Malkasian GD Jr, O'Brien PC, Naessens JM. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol. 1990 Feb; 162 (2):418-23; discussion 423-6
    View PubMed
  215. Colvard DS, Graham ML, Berg NJ, Ingle JN, Schaid DJ, Podratz KC, Spelsberg TC. Identification of putative nonfunctional steroid receptors in breast and endometrial cancer. Recent Results Cancer Res. 1990; 118:233-41
    View PubMed
  216. Podratz KC. Hormonal therapy in endometrial carcinoma. Recent Results Cancer Res. 1990; 118:242-51
    View PubMed
  217. Edmonson JH, McCormack GM, Wieand HS, Kugler JW, Krook JE, Stanhope CR, Everson LK, Laurie JA, Ebbert LP, Malkasian GD Jr, Abu-Ghazalek S, Podratz KC, Barlow JF, Weiland LH. Cyclophosphamide-displatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst. 1989 Oct 4; 81:1500-4.
  218. Nielsen SN, Podratz KC, Scheithauer BW, O'Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol. 1989 Sep; 34 (3):372-8
    View PubMed
  219. Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC. Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol. 1989 Sep; 34 (3):317-22
    View PubMed
  220. Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong SJ, Morley GW, Podratz KC, Shingleton HM. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study. Gynecol Oncol. 1989 Sep; 34 (3):258-62
    View PubMed
  221. Lentz SS, McKean DJ, Kovach JS, Podratz KC. Phenotypic and functional characteristics of mononuclear cells in ovarian carcinoma tumors. Gynecol Oncol. 1989 Aug; 34 (2):136-40
    View PubMed
  222. Martinez A, Schray M, Podratz K, Stanhope R, Podratz K, Malkasian G. Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys. 1989 Aug; 17 (2):371-7
    View PubMed
  223. Alvarez RD, Soong S, Kinney WK, Reid GC, Schray MF, Podratz KC, Morley GW, Shingleton HM. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol. 1989; 35:130-35.
    View PubMed
  224. Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, Malkasian GD, Stanhope CR, Wilson TO. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol. 1988 Sep; 31 (1):9-24
    View PubMed
  225. Schray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GD Jr, Sikic BI. Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J Clin Oncol. 1988 Sep; 6: (9)1433-9.
    View PubMed
  226. Kinney WK, Egorshin EV, Podratz KC. Wertheim hysterectomy in the geriatric population. Gynecol Oncol. 1988 Sep; 31 (1):227-32
    View PubMed
  227. Podratz KC. Response. Gynecol Oncol. 1988 Sep; 31:24.
  228. Martinez A, Podratz KC, Schray MF, Malkasian GD Jr. Results of whole abdominopelvic irradiation with nodal boost for patients with endometrial cancer at high risk of failure in the peritoneal cavity. Hematol Oncol Clin North Am. 1988 Sep; 2:431-446.
    View PubMed
  229. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988 Aug; 159 (2):341-6
    View PubMed
  230. Podratz KC, Malkasian GD Jr, Wieand HS, Cha SS, Lee RA, Lee RA, Stanhope CR, Williams TJ. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol. 1988 Mar; 29 (3):274-82
    View PubMed
  231. Buskirk SJ, Schray MF, Podratz KC, Lee RA, Lee RA, Stanhope CR, Gaffey TA, Weber FC, Earle JD, Naessens JM, Malkasian GD. Ovarian dysgerminoma: a retrospective analysis of results of treatment, sites of treatment failure, and radiosensitivity. Mayo Clin Proc. 1987 Dec; 62 (12):1149-57
    View PubMed
  232. Schray MF, Podratz KC, Malkasian GD. Fallopian tube cancer: the role of radiation therapy. Radiother Oncol. 1987 Dec; 10 (4):267-75
    View PubMed
  233. Tsushima K, Podratz KC, Stanhope CR, Lieber MM. In vitro chemotherapy sensitivity testing of human ovarian carcinoma: comparison of optical colony counting and [3H]thymidine incorporation assays. Gynecol Oncol. 1987 Oct; 28 (2):170-80
    View PubMed
  234. Malkasian GD Jr, Podratz KC, Stanhope CR, Ritts RE Jr, Zurawski VR Jr. CA 125 in gynecologic practice. American Journal of Obstetrics & Gynecology. 1986 Sep; 155(3):515-8.
    View PubMed
  235. Stanhope CR, Symmonds RE, Lee RA, Williams TJ, Podratz KC, O'Brien PC. Urinary diversion with use of ileal and sigmoid conduits. American Journal of Obstetrics & Gynecology. 1986 Aug; 155(2):288-92.
    View PubMed
  236. Podratz KC, Podczaski ES, Gaffey TA, O'Brien PC, Schray MF, Malkasian GD. Primary carcinoma of the fallopian tube. American Journal of Obstetrics & Gynecology. 1986 Jun; 154(6):1319-26.
    View PubMed
  237. Schray MF, Martinez A, Howes AE, Ballon SC, Podratz KC, Sikic BI, Malkasian GD. Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecol Oncol. 1986 May; 24(1):68-80.
    View PubMed
  238. Edmonson JH, McCormack GW, Fleming TR, Cullinan SA, Krook JE, Malkasian GD, Podratz KC, Mailliard JA, Jefferies JA, Barlow JF. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep. 1985 Nov; 69(11):1243-8.
    View PubMed
  239. Podratz KC, O'Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstetrics & Gynecology. 1985 Jul; 66(1):106-10.
    View PubMed
  240. Podratz KC, Malkasian GD Jr, Hilton JF, Harris EA, Gaffey TA. Second-look laparotomy in ovarian cancer: evaluation of pathologic variables. American Journal of Obstetrics & Gynecology. 1985 May 15; 152(2):230-8.
    View PubMed
  241. Edmonson J, McCormack G, Fleming T, Cullinan S, Krook J, Malkasian G, Podratz K, Mailliard J, Jefferies J, Barlow J, Windschitl H. Comparison of cyclophosphamide and cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas Cancer Treat Rep. 1985; 69:1243-1248.
  242. Podratz KC. Melanoma of the vulva. Postgraduate Obstetrics & Gynecology. 1984 Jun; 4:1-6.
  243. Heath PM, Woods JE, Podratz KC, Arnold PG, Irons GB Jr. Gracilis myocutaneous vaginal reconstruction. Mayo Clin Proc. 1984 Jan; 59(1):21-4.
    View PubMed
  244. Podratz KC, Gaffey TA, Symmonds RE, Johansen KL, O'Brien PC. Melanoma of the vulva: an update. Gynecol Oncol. 1983 Oct; 16(2):153-68.
    View PubMed
  245. Williams TJ, Lieber MM, Podratz KC, Malkasian GD Jr. Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies. American Journal of Obstetrics & Gynecology. 1983 Apr 15; 145(8):940-7.
    View PubMed
  246. Podratz KC, Symmonds RE, Taylor WF, Williams TJ. Carcinoma of the vulva: analysis of treatment and survival. Obstetrics & Gynecology. 1983 Jan; 61(1):63-74.
    View PubMed
  247. Williams TJ, Lieber MM, Podratz KC, Malkasian GD Jr. Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies. Trans Am Gynecol Obstet Soc. 1983; 1:44-51.
  248. Podratz KC, Symmonds RE, Taylor WF. Carcinoma of the vulva: Analysis of treatment failures. Gynakol Geburtshilfliche Rundsch. 1983; 23(3):212-3.
  249. Podratz KC, Symmonds RE, Taylor WF. Carcinoma of the vulva: analysis of treatment failures. American Journal of Obstetrics & Gynecology. 1982 Jun 1; 143(3):340-51.
    View PubMed
  250. Podratz KC. Alcoholic ketoacidosis in pregnancy. Obstetrics & Gynecology. 1978 Jul; 52(1 Suppl):54S-57S.
    View PubMed
  251. Podratz KC, Munns TW, Katzman PA. Estrogen induction of 20alpha-hydroxysteroid dehydrogenase in mouse vaginal tissue. Steroids. 1974 Dec; 24(6):765-74.
    View PubMed
  252. Munns TW, Podratz KC, Katzman PA. Methylation of the guanine bases of transfer RNA. Biochem Biophys Res Commun. 1974 Jul 24; 59(2):496-501.
    View PubMed
  253. Munns TW, Podratz KC, Katzman PA. A method for the determination of the methylated constituents of transfer ribonucleic acid. Biochemistry. 1974; 13:4409-4416.
    View PubMed
  254. Podratz KC, Munns TW, Katzman PA. Metabolism of progesterone in mouse vagina tissues. Steroids. 1974; 24:775-792.
    View PubMed
  255. Munns TW, Podratz KC, Katzman PA. Separation of methylated bases of ribonucleic acid by two-dimensional thin-layer chromatography. J Chromatogr. 1973 Feb 28; 76(2):401-6.
    View PubMed
  256. Podratz KC, Katzman PA. Effects of estradiol on uptake and retention of progesterone by the vagina of the ovariectomized mouse. Fed Proc. 1968; 27:497-498.